{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:50:24Z","timestamp":1791957024587,"version":"4.3.4"},"reference-count":0,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Drug-induced lupus erythematosus (DILE) syndromes are documented complications of chemotherapeutic agents, including paclitaxel. Subacute cutaneous lupus erythematosus (SCLE) is a distinct DILE syndrome presenting with characteristic annular or papulosquamous skin lesions in a photosensitive distribution with associated high anti-SSA titres. Previously, DILE syndromes complicating paclitaxel therapy have been attributed to polyethoxylated castor oil (Kolliphor EL: BASF, Ludwigshafen, Germany), the biologic solvent included in the drug\u2019s original formulation (Taxol: Bristol\u2013Myers Squibb, Montreal, QC), rather than the parent chemotherapy molecule. Here, we report a characteristic case of drug-induced SCLE complicating treatment with nanoparticle albumin bound (nab)\u2013paclitaxel (Abraxane: Celgene, Summit, NJ, U.S.A.), a solvent-free taxane formulation. The pertinent English-language literature is also discussed. This case report is the first to link solvent-free paclitaxel with SCLE, and it suggests that the parent molecule is responsible for the reaction.<\/jats:p>","DOI":"10.3747\/co.20.1546","type":"journal-article","created":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T18:47:18Z","timestamp":1382467638000},"page":"484-487","source":"Crossref","is-referenced-by-count":27,"title":["Drug-Induced Subacute Cutaneous Lupus Erythematosus Associated with Nab-Paclitaxel Therapy"],"prefix":"10.3390","volume":"20","author":[{"given":"N.W.D.","family":"Lamond","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Younis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Purdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.S.","family":"Dorreen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2013,10,1]]},"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/20\/5\/1546\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T07:56:18Z","timestamp":1613721378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/20\/5\/1546"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,1]]},"references-count":0,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2013,10]]}},"alternative-id":["co.20.1546"],"URL":"https:\/\/doi.org\/10.3747\/co.20.1546","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,1]]}}}